Skip to main content
Onesource Specialty Pharma Limited logo

Onesource Specialty Pharma Limited — Investor Relations & Filings

Ticker · ONESOURCE ISIN · INE013P01021 LEI · 335800TP5C932B9IQT98 BSE.NS Manufacturing
Open in API
Filings indexed 156 across all filing types
Latest filing 2025-01-24 Major Shareholding Noti…
Country IN India
Listing BSE.NS ONESOURCE

About Onesource Specialty Pharma Limited

https://www.onesourcecdmo.com/

Onesource Specialty Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) providing integrated solutions for complex pharmaceutical products. The company focuses on the development and large-scale manufacturing of specialty injectables, softgel capsules, and complex formulations. Its service portfolio encompasses the entire product lifecycle, including formulation development, clinical trial supply, and commercial-stage production. Onesource operates advanced manufacturing facilities designed to meet global regulatory standards, catering to diverse therapeutic areas. By leveraging technical expertise in sterile products and differentiated dosage forms, the organization supports global pharmaceutical partners in bringing high-entry-barrier medicines to market. The platform is built on a foundation of quality compliance and operational excellence to ensure the delivery of critical healthcare solutions.

Recent filings

Filing Released Lang Actions
Updates
Major Shareholding Notification Classification · 95% confidence The document is an intimation under Regulation 31(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to the shareholding pattern of the company for the quarter ended December 31, 2024. It includes detailed tables showing significant beneficial owners and foreign ownership limits. The document is a regulatory disclosure about shareholding, not a full financial report or earnings release. It is a formal notification to stock exchanges about shareholding data, which fits the category of Major Shareholding Notification (MRQ). The document length is 4428 characters, which is sufficient to contain substantive shareholding information rather than just an announcement or certification. Therefore, the appropriate classification is MRQ.
2025-01-24 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges (NSE and BSE) regarding the authorization of Key Managerial Personnel (KMPs) for disclosure purposes under SEBI LODR regulations. It lists names and contact details of authorized personnel. There is no financial data, no report attached or referenced, and no indication of a meeting or voting results. The document is an official regulatory announcement about management contacts for compliance and disclosure, fitting the category of a general regulatory announcement rather than a financial report or meeting material. Given the short length (1693 characters) and content, it is best classified as a Regulatory Filing (RNS).
2025-01-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification under SEBI Listing Regulations about an upcoming Board of Directors meeting to approve unaudited financial results for the quarter and nine months ended December 31, 2024. It also announces an investor conference call scheduled to discuss these financial results. The document does not contain the financial results themselves but rather informs about the meeting and the call. The length is short (3191 characters), and it serves as an announcement rather than a full report or transcript. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not contain the actual earnings release or call transcript.
2025-01-24 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-01-24 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding a scheduled Board of Directors meeting to consider and approve financial results for the quarter ended December 31, 2024. It references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about board meetings and related decisions. The document does not contain the financial results themselves, nor detailed financial data or analysis, but is an announcement of an upcoming board meeting where such results will be considered. The document length is short (1764 characters), and it serves as an intimation or notice rather than a report or transcript. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board meetings and related management information.
2025-01-24 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a formal letter from OneSource Specialty Pharma Limited addressed to the National Stock Exchange of India and BSE Limited. It announces the receipt of final listing and trading approval for its equity shares and specifies the start date for trading on these exchanges. The content is an official announcement regarding the listing and trading approval of shares, not a financial report, earnings release, or detailed regulatory filing. The document length is short (1642 characters), and it serves as a notification of a capital market event (listing approval). This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as listing approvals.
2025-01-23 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.